Using new molecules to activate a signaling pathway that may help treat Alzheimer's disease
Activation of TGFb signaling using novel SMAD4 molecular glues
This study is looking at how a specific process in the brain might help us understand Alzheimer's disease better and find new treatments that could slow down memory loss and improve thinking skills for people living with this condition.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10939445 on NIH RePORTER |
What this research studies
This research investigates the role of a specific signaling pathway, known as TGFβ-SMAD, in Alzheimer's disease, which is characterized by memory loss and cognitive decline. The study focuses on how neuroinflammation contributes to the disease and aims to develop new therapeutic strategies that can restore the impaired signaling. Researchers have identified novel small molecules that act as 'molecular glues' to stabilize key proteins involved in this pathway, potentially leading to improved neuronal health and reduced amyloid accumulation. Patients may benefit from therapies that target this pathway, which could slow disease progression and improve cognitive function.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those experiencing early symptoms of cognitive decline.
Not a fit: Patients with other forms of dementia unrelated to Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that slow the progression of Alzheimer's disease and improve quality of life for patients.
How similar studies have performed: While the approach of targeting TGFβ-SMAD signaling is promising, it is relatively novel and has not been extensively tested in the context of Alzheimer's disease.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Mo, Xiulei — Emory University
- Study coordinator: Mo, Xiulei
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.